Vaxcyte, Inc. PCVX
New risk paragraphs, branching off last year
Each branch is a paragraph in Risk Factors with nothing like it in the 10-K filed Feb 25, 2025. A box jumps to the paragraph as filed, below.
Paragraphs with nothing like them in last year's 10-K
19 paragraphs in Risk Factors of the 10-K filed Feb 24, 2026 with nothing like them in the 10-K filed Feb 25, 2025. Quoted exactly. Paragraphs that were only edited are under 10-K change.
New pediatric vaccines that receive an ACIP preferred recommendation are almost universally adopted, and adult vaccines that receive a preferred recommendation are widely adopted. Recent changes to federal vaccine policy have introduced new uncertainties regarding the regulatory, legal, and reimbursement landscape for vaccines in the United States. Such changes have resulted in the American Academy of Pediatrics and other recommending bodies or organizations to generate their own recommended pediatric vaccine schedule. We may need to engage with additional professional societies or organizations to secure access for both adults and infants.
The success of our business depends in large part upon our ability to identify, develop and commercialize products based on our cell-free protein synthesis platform. In addition to our PCV franchise, our pipeline includes preclinical vaccine
For example, we announced in August 2025 that preclinical data for VAX-PG demonstrated an acceptable safety profile
but not sufficient efficacy signals to support further investment, and we therefore discontinued further development of that
•significant changes in trade policies, price and exchange controls and other regulatory requirements;
For example, our agreements with Lonza are denominated in Swiss Franc (“CHF”). Fluctuations in the exchange rate for CHF may increase our costs and affect our operating results.
Show the other 8
On July 4, 2025, the One Big Beautiful Bill Act ("OBBBA") was signed into law in the United States, and contains a wide range of tax reform provisions, including extending and modifying certain key Tax Act provisions, such as 100% bonus depreciation and the business interest expense limitation. Additionally, the OBBBA repealed mandatory capitalization and amortization of domestic R&D expenses, reverting to the immediate expensing of R&D expenditures for tax years beginning in 2025. Further, the OBBBA provided for an election to deduct the remaining unamortized domestic R&D expense as of December 31, 2024, either entirely in 2025 or over two years, in 2025 and 2026.
The FDA has recently indicated consideration of additional evidentiary standards for certain vaccine approvals, including potential requirements for expanded clinical trials, additional safety data, and additional post-marketing surveillance. If applied, these changes may increase the time, cost, and complexity of developing and commercializing our vaccine candidates, and may delay or prevent the approval of new vaccines or updates to existing products.
Changes to federal vaccine recommendations could lower utilization, change reimbursement for our products, and create access challenges because vaccine coverage requirements, including limits on cost-sharing, for nearly all insurers are linked to ACIP and CDC recommendations.These changes may affect the scope of liability protections under the National Vaccine Injury Compensation Program, insurance coverage and reimbursement for certain vaccines, and the requirements for state-level vaccine mandates. Ongoing and potential reforms to the federal vaccine injury compensation system, as well as increased state-level divergence from federal recommendations, may further impact our business, operations, and financial condition.
and teaching hospitals, as well as information regarding ownership and investment interests held by the physicians described above and their immediate family members;
Additional action has been taken to change healthcare policies. For example, the federal government has shown substantial interest in taking a variety of measures aimed at lowering U.S. prescription drug prices to align with the lowest prices available for the same drugs in comparable developed nations (so called “most favored nation” pricing), including through CMMI models.
measures, and, in some cases, policies to encourage importation from other countries (subject to federal approval) and bulk purchasing. The OBBBA will also reduce funds for Medicaid programs, which are administered by the states.
The development, review and approval of our product candidates are subject to the operational capacity, processes and resource levels of regulatory authorities, which may fluctuate over time and could delay or adversely affect our business.
Significant changes and volatility in trade policies could materially affect our business, financial condition, liquidity and results of operations, and stock price.
International trade policies are subject to periodic revision and may change in response to economic, geopolitical or national security considerations. The U.S. government and certain foreign governments have recently announced new or increased tariffs on imported goods, and additional tariffs or increases in tariffs could be assessed in the future. Pharmaceuticals have historically been exempt from tariffs and have, thus far, been exempt from recently imposed tariffs.
However, the government has recently launched an investigation under Section 232 of the Trade Expansion Act of 1962 to determine the effects on national security of imports of pharmaceuticals and pharmaceutical ingredients, and their derivative products. This investigation is intended to cover both finished generic and branded drug products, medical countermeasures, critical inputs such as active pharmaceutical ingredients and key starting materials, and derivative products of those items. It is possible that this investigation will result in the imposition of tariffs on a range of pharmaceutical products and ingredients, in ways that negatively impact certain aspects of our manufacturing process for our clinical trial product materials and supplies, the level of expenses related to our vaccine candidates or preclinical and clinical development programs, and our business.
We rely on third-party manufacturers with global operations, so our business may be impacted by tariffs. We do not sell
any commercial products nor do we expect to do so in the immediate future, so we cannot pass on the increased costs from
the tariffs to customers. Therefore, we will need to absorb any increased costs, which will put further financial strain on our
Paragraphs in the 10-Q filed Nov 4, 2026 that were not in the one before
New in the latest 10-Q
65 paragraphs in the 10-Q filed Nov 4, 2026 with nothing like them in the 10-Q filed Aug 5, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.
Financial statements and notes
Right-of-use assets obtained in exchange for finance lease liabilities $ 112,955 $ —
Read in the 10-Q
Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to 12 years. Leasehold improvements are amortized over the shorter of the expected life or lease term. Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the consolidated balance sheets and the resulting gain or loss is reflected in the consolidated statements of operations in the period realized.
Read in the 10-Q
We evaluate an arrangement at inception to determine whether an arrangement is a lease or contains an embedded lease in accordance with Accounting Standards Codification ("ASC") 842. An arrangement contains an embedded lease if it conveys the right to control the use of an identified asset for a period of time in exchange for consideration. In addition, we determine whether a lease meets the classification criteria of a finance or operating lease at the lease commencement date considering whether: (i) the lease transfers ownership of the underlying asset to the lessee at the end of the lease term; (ii) the lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise; (iii) the lease term is for a major part of the remaining economic life of the underlying asset; (iv) the present value of the sum of the lease payments and residual value guaranteed by the lessee equals or exceeds substantially all of the fair value of the underlying asset; and (v) the underlying asset is such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. Lease agreements that include lease and non-lease components are accounted for as a single lease component. The lease term is the non-cancelable period of the lease and includes options to extend or terminate the lease when it is reasonably certain that an option will be exercised. Lease agreements with non-cancelable terms of less than 12 months are not recorded on our consolidated balance sheets.
Read in the 10-Q
Operating leases are included in Operating lease right-of-use ("ROU") assets, Operating lease liabilities - current and Operating lease liabilities - non-current in our consolidated balance sheets. Finance leases are included in Finance lease ROU assets, Finance lease liabilities - current and Finance lease liabilities - non-current in our consolidated balance sheets. ROU assets represent our right to use the underlying assets for the lease term, and lease liabilities represent our obligation to make lease payments arising from the leases. Lease ROU assets and liabilities for both operating leases and finance leases are recognized at the lease commencement date based on the present value of lease payments that are fixed or in substance fixed under ASC 842 over the lease term. In determining the present value of lease payments, if the rate implicit in the lease is not readily determinable, we use our incremental borrowing rate based on the information available at the lease commencement date. We determine the incremental borrowing rate based on an analysis of corporate bond yields with a credit rating similar to ours. The determination of our incremental borrowing rate requires management judgment, including development of a synthetic credit rating and cost of debt. We believe that the estimates used in determining the incremental borrowing rate are reasonable based upon current facts and circumstances. ROU assets also include adjustments for prepayments and accrued lease payments and exclude lease incentives. ROU assets and lease liabilities may include options to extend or terminate leases if it is reasonably certain that we will exercise such options. Variable lease costs, which are dependent on usage, a rate or index, including common area maintenance charges, are expensed as incurred. For operating leases, ROU assets are amortized as rent expense on a straight-line basis over the lease term. For finance leases, ROU assets are amortized on a straight-line basis over the shorter of the estimated useful life of the underlying asset or the lease term, and interest expense on the finance lease liability is recognized using the effective interest method over the lease term.
Read in the 10-Q
evaluating the impact of this guidance on our financial statement disclosures, which we expect to be expanded beginning with our Annual Report on Form 10-K for the year ending December 31, 2027.
Read in the 10-Q
Show the other 60
We had no Level 3 securities either as of September 30, 2026 or December 31, 2025.
Read in the 10-Q
See Note 5, "Balance Sheet Details," for further details related to Vaxcyte-owned facility buildout and equipment, and Note 6, "Leases," for further details related to facility buildout expenditures owned and controlled by Lonza, each as of September 30, 2026.
Read in the 10-Q
In August 2026, we placed into service $ 138.5 million of company-owned equipment and $ 63.1 million of leasehold improvements pertaining to the Suite pursuant to the Lonza Commercial Manufacturing and Supply Agreement.
Read in the 10-Q
Depreciation of the equipment is recognized on a straight-line method over the shorter of the estimated useful life or the term of the agreement.
Read in the 10-Q
Property and equipment, net as of September 30, 2026 and December 31, 2025 consisted of the following:
Read in the 10-Q
Other assets as of September 30, 2026 and December 31, 2025 consisted of the following:
Read in the 10-Q
We have concluded that the Lonza Commercial Manufacturing and Supply Agreement contains an embedded lease, which was deemed to have commenced following completion of construction and certification of the Suite for commercial operation and the transfer to the Lonza operations team in August 2026. Upon lease commencement, we evaluated the embedded lease against the classification criteria in ASC 842 and determined that it met at least one of the criteria for finance lease classification. Accordingly, we classified the embedded lease as a finance lease. As of September 30, 2026, we recorded finance lease ROU assets of $ 301.7 million and corresponding lease liabilities of $ 107.8 million on our condensed consolidated balance sheet. The ROU assets include (i) the initial measurement of the lease liabilities and (ii) amounts previously accounted for as prepaid lease payments prior to the lease commencement date, specifically facility buildout expenditures that are owned and controlled by Lonza, the Repurposing Fee and costs associated with certification of the Suite for commercial operation. The finance lease liabilities were measured at the present value of the remaining lease payments, discounted using our incremental borrowing rate.
Read in the 10-Q
The following tables present additional information for our operating and finance leases:
Read in the 10-Q
On November 1, 2026, the lease of the final floor space of the Additional Premises commenced. We are currently assessing the accounting effects of the lease commencement on our consolidated financial statements.
Read in the 10-Q
(n=475). In this trial, VAX-31 met all prespecified primary endpoints across age groups studied compared to PCV20 and PCV21.
Read in the 10-Q
• VAX-31 met all prespecified co-primary immunogenicity endpoints in adults 50 and older:
Read in the 10-Q
• All 28 VAX-31 serotypes shared with PCV20 and/or PCV21 met the prespecified noninferiority criteria (lower bound of the 95% confidence interval (“LBCI”) >0.667) with the prespecified Hochberg multiplicity adjustment.
Read in the 10-Q
• For the 11 serotypes shared by VAX-31, PCV20 and PCV21, VAX-31 met all 11 primary noninferiority assessments based on opsonophagocytic activity (“OPA”) geometric mean ratios (“GMRs”). For each serotype, the prespecified analysis required noninferiority against one or both comparators, using an OPA GMR noninferiority criterion of LBCI >0.667 with the prespecified Hochberg multiplicity adjustment.
Read in the 10-Q
• For the nine serotypes only in VAX-31 and PCV20, all nine met the prespecified OPA GMR noninferiority criterion (LBCI >0.667).
Read in the 10-Q
• For the eight serotypes only in VAX-31 and PCV21, all eight met the prespecified OPA GMR noninferiority criterion (LBCI >0.667).
Read in the 10-Q
• The three serotypes unique to VAX-31 and cross-reactive serotype 20B met the OPA GMR superiority criterion (LBCI >2.0) with prespecified Hochberg multiplicity adjustment.
Read in the 10-Q
• For the prespecified primary immunobridging endpoint, VAX-31 met the noninferiority criterion (LBCI >0.667) for all 32 serotype (31 vaccine serotypes plus cross-reactive serotype 20B) OPA GMR comparisons in adults aged 18-49 compared to adults aged 50-64.
Read in the 10-Q
• In the prespecified individual comparator analyses, VAX-31 met the noninferiority criterion (LBCI >0.667) for 20 of 20 serotypes shared with PCV20 and 17 of 19 shared with PCV21. Compared to PCV21, serotypes 3 and 12F missed the LBCI >0.667 noninferiority criterion, but did meet the historical LBCI >0.5 threshold; compared to PCV20, VAX-31 met the LBCI>0.667 noninferiority criterion.
Read in the 10-Q
enrollment in the Low Dose arm. The Middle and High Dose arms continued as planned.
Read in the 10-Q
• Reported Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31: In October 2026, we announced positive results from the OPUS-1 trial. VAX-31 was well tolerated and demonstrated a safety profile similar to PCV20 and PCV21 across all ages studied. VAX-31 met all prespecified primary endpoints across age groups studied compared to PCV20 and/or PCV21. Importantly, VAX-31 met all prespecified co-primary immunogenicity endpoints in adults 50 and older:
Read in the 10-Q
• All 28 serotypes shared with PCV20 and/or PCV21 met the prespecified noninferiority criteria of LBCI >0.667 with the prespecified Hochberg multiplicity adjustment.
Read in the 10-Q
• For the 11 serotypes shared by VAX-31, PCV20 and PCV21, VAX-31 met all 11 primary noninferiority assessments based on OPA GMRs. For each serotype, the prespecified analysis required noninferiority against one or both comparators, using an OPA GMR noninferiority criterion of LBCI >0.667 with the prespecified Hochberg multiplicity adjustment.
Read in the 10-Q
• For the nine serotypes shared only with PCV20, all nine met the prespecified OPA GMR noninferiority criterion (LBCI >0.667).
Read in the 10-Q
• For the eight serotypes shared only with PCV21, all eight met the prespecified OPA GMR noninferiority criterion (LBCI >0.667).
Read in the 10-Q
• The three VAX-31 unique serotypes and cross-reactive serotype 20B met the OPA GMR superiority criterion (LBCI >2.0) with the prespecified Hochberg multiplicity adjustment.
Read in the 10-Q
• For the prespecified primary immunobridging endpoint, VAX-31 met the OPA GMR noninferiority criterion (LBCI >0.667) for all 32 serotype (31 vaccine serotypes plus cross-reactive serotype 20B) OPA GMR comparisons in adults aged 18-49 compared to adults aged 50-64.
Read in the 10-Q
• In the OPUS-1 prespecified individual comparator analyses, VAX-31 met the noninferiority criterion (LBCI >0.667) for 20 of 20 serotypes shared with PCV20 and 17 of 19 shared with PCV21. Compared to PCV21, serotypes 3 and 12F missed the LBCI >0.667 noninferiority criterion, but did meet the historical LBCI >0.5 threshold; compared to PCV20, VAX-31 met the LBCI>0.667 noninferiority criterion.
Read in the 10-Q
• Appointed Chief Medical Officer and Chief Legal Officer: In September 2026, we announced the appointments of experienced industry leaders Luis Jodar, Ph. D. as Chief Medical Officer and David McAvoy, J.D. as Chief Legal Officer. Dr. Jodar has more than 30 years of experience in vaccine development and launch across industry, international health organizations and academia. He spent 17 years at Pfizer Inc., most recently as Senior Vice President and Chief Medical Officer for Vaccines and Infectious Diseases. Mr. McAvoy brings more than three decades of legal leadership in the biopharmaceutical industry, including serving as Executive Vice President and Chief Legal Officer of Teva Pharmaceutical Industries Ltd.
Read in the 10-Q
above, we are unable to determine the duration and completion costs of our research and development projects or if, when and to what extent we will generate revenue from the commercialization and sale of our vaccine candidates.
Read in the 10-Q
The exercise price of each pre-funded warrant equals $0.001 per share and each pre-funded warrant is exercisable from the date of issuance until fully exercised, subject to an ownership limitation.
Read in the 10-Q
The 2032 Notes were issued pursuant to, and are governed by, an indenture (the “Base Indenture”), dated as of October 9, 2026, between us and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), as supplemented by a First Supplemental Indenture (the “Supplemental Indenture,” and the Base Indenture, as supplemented by the Supplemental Indenture, the “Indenture”), dated as of October 9, 2026, between us and the Trustee.
Read in the 10-Q
The 2032 Notes are senior, unsecured obligations and will accrue interest at a rate of 1.50% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, beginning on April 15, 2027. The 2032 Notes will mature on October 15, 2032 unless earlier repurchased, redeemed or converted. Before July 15, 2032, noteholders will have the right to convert their 2032 Notes only upon the occurrence of certain events. From and after July 15, 2032, noteholders may
Read in the 10-Q
convert their 2032 Notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. We will settle conversions by paying or delivering, as applicable, cash, shares of our common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate is 11.1607 shares of common stock per $1,000 principal amount of 2032 Notes, which represents an initial conversion price of approximately $89.60 per share of common stock. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events. In addition, if certain corporate events that constitute a “Make-Whole Fundamental Change” (as defined in the Indenture) occur, then the conversion rate will, in certain circumstances, be increased for a specified period of time.
Read in the 10-Q
The 2032 Notes will be redeemable (a “provisional redemption”), in whole or in part (subject to certain limitations described below), at our option at any time, and from time to time, on or after October 22, 2029 and on or before the 20th scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the 2032 Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date, but only if the last reported sale price per share of common stock exceeds 130% of the conversion price on (x) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date we send the related redemption notice; and (y) the trading day immediately before the date we send such notice. However, we may not redeem less than all of the outstanding 2032 Notes pursuant to a provisional redemption unless at least $75.0 million aggregate principal amount of 2032 Notes are outstanding and not called for redemption as of the time we send the related redemption notice. In addition, calling any 2032 Note for provisional redemption will constitute a Make-Whole Fundamental Change with respect to that 2032 Note, in which case the conversion rate applicable to the conversion of that 2032 Note will be increased in certain circumstances if it is converted after it is called for provisional redemption.
Read in the 10-Q
In addition, we will also have the right to redeem (a “cleanup redemption”) all, but not less than all, of the 2032 Notes, at any time, at a cash redemption price equal to the principal amount of the 2032 Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date, but only if the principal amount of the 2032 Notes outstanding at the time we send the related redemption notice is less than 10% of the aggregate principal amount of the 2032 Notes originally issued. Calling the 2032 Notes for cleanup redemption will constitute a Make-Whole Fundamental Change, which will require us to increase the conversion rate in certain circumstances for a specified period of time.
Read in the 10-Q
If certain corporate events that constitute a “Fundamental Change” (as defined in the Indenture) occur, then, subject to a limited exception for certain cash mergers, noteholders may require us to repurchase their 2032 Notes at a cash repurchase price equal to the principal amount of the 2032 Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date. The definition of Fundamental Change includes certain business combination transactions involving us and certain de-listing events with respect to the common stock.
Read in the 10-Q
Risk Factors
preclinical 30-plus valent candidate. In October 2025, GSK announced the initiation of a Phase 1 study in Australia evaluating its 30-plus valent candidate in adults. In the fourth quarter of 2025, GSK removed its pediatric 24-valent candidate, which had previously advanced into a Phase 2 clinical trial program, from its publicly disclosed pipeline. GSK's disclosed pipeline lists a 30-plus valent pediatric candidate in Phase 1.
Read in the 10-Q
cannot provide any assurance that we will be able to successfully advance any of our existing or future vaccine candidates through the development process.
Read in the 10-Q
solution for handling cell-free extract during our clinical studies, such studies may be delayed, and we will incur additional costs;
Read in the 10-Q
view of interchangeability may allow more biosimilars to be automatically substituted for the reference product upon approval.
Read in the 10-Q
and teaching hospitals, as well as information regarding ownership and investment interests held by the physicians described above and their immediate family members;
Read in the 10-Q
do not meet evolving legal and regulatory standards, our reputation and financial results could be materially and adversely affected.
Read in the 10-Q
Our indebtedness and liabilities could limit the cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations and impair our ability to satisfy our obligations under the 2032 Notes.
Read in the 10-Q
As of the date of this Quarterly Report on Form 10-Q, we have $575.0 million principal amount of indebtedness outstanding under our 1.50% Convertible Senior Notes due 2032 (the “2032 Notes”). We may also incur additional indebtedness to meet future financing needs. Our indebtedness could have significant negative consequences for our security holders and our business, results of operations and financial condition by, among other things:
Read in the 10-Q
• requiring the dedication of a substantial portion of our cash flow from operations to service our indebtedness, which will reduce the amount of cash available for other purposes;
Read in the 10-Q
• diluting the interests of our existing stockholders as a result of issuing shares of our common stock upon conversion of the 2032 Notes; and
Read in the 10-Q
• placing us at a possible competitive disadvantage with competitors that are less leveraged than us or have better access to capital.
Read in the 10-Q
Our business may not generate sufficient funds, and we may otherwise be unable to maintain sufficient cash reserves, to pay amounts due under our indebtedness, including the 2032 Notes, and our cash needs may increase in the future. In addition, future indebtedness that we may incur may contain financial and other restrictive covenants that limit our ability to operate our business, raise capital or make payments under our other indebtedness. If we fail to comply with these covenants or to make payments under our indebtedness when due, then we would be in default under that indebtedness, which could, in turn, result in that and our other indebtedness becoming immediately payable in full.
Read in the 10-Q
We may be unable to raise the funds necessary to repurchase the 2032 Notes for cash following a fundamental change or to pay any cash amounts due upon maturity or conversion of the 2032 Notes, and our other indebtedness may limit our ability to repurchase the 2032 Notes or to pay any cash amounts due upon their maturity or conversion.
Read in the 10-Q
Holders of the 2032 Notes may, subject to a limited exception, require us to repurchase their 2032 Notes following a “fundamental change” (as defined in the indenture governing the 2032 Notes) at a cash repurchase price generally equal to the principal amount of the 2032 Notes to be repurchased, plus accrued and unpaid interest, if any. Upon maturity of the 2032 Notes, we must pay their principal amount and accrued and unpaid interest in cash, unless they have been previously repurchased, redeemed or converted. In addition, upon conversion, we will satisfy part or all of our conversion obligation in cash unless we elect to settle conversions solely in shares of our common stock. We may not have enough available cash or be able to obtain financing at the time we are required to repurchase the 2032 Notes or pay any cash amounts due upon their maturity or conversion. In addition, applicable law, regulatory authorities and the agreements governing our other indebtedness may restrict our ability to repurchase the 2032 Notes or to pay any cash amounts due upon their maturity or conversion. Our failure to repurchase 2032 Notes or to pay any cash amounts due upon their maturity or conversion when required will constitute a default under the indenture governing the 2032 Notes. A default under the indenture governing the 2032 Notes or the fundamental change itself could also lead to a default under agreements governing our other indebtedness, which may result in that other indebtedness becoming immediately payable in full. We may not have sufficient funds to satisfy all amounts due under the other indebtedness and the 2032 Notes.
Read in the 10-Q
Provisions in the indenture governing the 2032 Notes could delay or prevent an otherwise beneficial takeover of us.
Read in the 10-Q
Certain provisions in the 2032 Notes and the indenture governing the 2032 Notes could make a third-party attempt to acquire us more difficult or expensive. For example, if a takeover constitutes a fundamental change, then, subject to a limited exception, holders of the 2032 Notes will have the right to require us to repurchase their 2032 Notes for cash. In addition, if a takeover constitutes a “make-whole fundamental change” (as defined in the indenture governing the 2032 Notes), then we may be required to temporarily increase the conversion rate. In either case, and in other cases, our obligations under the 2032 Notes and the indenture governing the 2032 Notes could increase the cost of acquiring us or otherwise discourage a third party from acquiring us, including in a transaction that holders of the 2032 Notes or holders of our common stock may view as favorable.
Read in the 10-Q
The accounting method for the 2032 Notes could adversely affect our reported financial condition and results.
Read in the 10-Q
The accounting method for reflecting the 2032 Notes on our balance sheet, accruing interest expense for the 2032 Notes and reflecting the underlying shares of our common stock in our reported diluted earnings per share may adversely affect our reported earnings and financial condition.
Read in the 10-Q
We are currently assessing the accounting effects of the 2032 Notes on our consolidated financial statements. In accordance with applicable accounting standards, we expect that the 2032 Notes will be reflected as a liability on our balance sheets, with the initial carrying amount equal to the principal amount of the 2032 Notes, net of issuance costs. The issuance costs would be treated as a debt discount for accounting purposes, which would be amortized into interest expense over the term of the 2032 Notes. As a result of this amortization, the interest expense that we expect to recognize for the 2032 Notes for accounting purposes could be greater than the cash interest payments we will pay on the 2032 Notes, which would result in lower reported income.
Read in the 10-Q
Furthermore, if any of the conditions to the convertibility of the 2032 Notes is satisfied, then we may be required under applicable accounting standards to reclassify the liability carrying value of the 2032 Notes as a current, rather than a long-term, liability. This reclassification could be required even if no noteholders convert their 2032 Notes and could materially reduce our reported working capital.
Read in the 10-Q
Other information
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Read in the 10-Q
On November 3, 2026, the Company entered into an amendment to the Executive Change in Control and Severance Agreement between the Company and Mikhail Eydelman, its Senior Vice President, General Counsel (as so amended, the “Amended Agreement”). In connection with certain organizational changes implemented as of August 31, 2026 impacting Mr. Eydelman’s role, Mr. Eydelman and the Company have formally agreed that he will remain employed until at least the earlier of (i) May 31, 2027 (the “Scheduled Date”), or (ii) the date on which an Early Termination Event occurs (the period between August 31, 2026 and the earlier to occur of the Scheduled Date or Early Termination Event, the “Continued Employment Period”). During the Continued Employment Period, Mr. Eydelman will continue to vest in his Company equity awards and to earn base salary and annual incentives as currently in effect. The Amended Agreement also preserves Mr. Eydelman’s Good Reason severance rights for the duration of the Continued Employment Period. Unless Mr. Eydelman’s employment continues past the Scheduled Date, upon his termination of employment for Good Reason, Mr. Eydelman will be entitled to receive the severance benefits that apply upon a termination of his employment for Good Reason under the Change in Control and Severance Agreement as previously disclosed, except that, pursuant to the Amended Agreement, the severance benefits to apply to Mr. Eydelman upon a Qualifying Termination are modified such that the references to 12 months have been reduced to 9 months.
Read in the 10-Q
Capitalized terms not otherwise defined herein have the meanings set forth in the Amended Agreement.
Read in the 10-Q
The foregoing description of the Amended Agreement is only a summary and is qualified in its entirety by the Second Amendment to Change in Control and Severance Agreement between Vaxcyte, Inc. and Mikhail Eydelman, dated November 3, 2026, disclosed herewith.
Read in the 10-Q
The 10-Q's risk factors against the 10-K
Item 1A of the 10-Q filed Nov 4, 2026 against Item 1A of the 10-K filed Feb 24, 2026.
A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed.
Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed,
Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal
(cut words struck through, new words highlighted).
Text on the page, not a score; each links to the filing at sec.gov.
Show the other 19
The first 24 of 54 are shown (at most 12 of each type).
Phrases used for the first time
Two-word phrases in Risk Factors of the 10-K filed Feb 24, 2026 that are in none of the 1 earlier 10-Ks stored, back to Feb 25, 2025
Where each one is used
- thermo fisher: We expect to continue to rely on third-party manufacturers and suppliers if we receive regulatory approval for any PCV or any other vaccine candidates. For example, in October 2023, we entered into a pre-commercial services and commercial manufacturing supply agreement (the “Lonza Commercial Manufacturing and...
- trade policies: We rely on third-party contract manufacturers to manufacture preclinical and clinical trial product materials and supplies for our needs. There can be no assurance that our preclinical and clinical development product supplies will not be limited or interrupted or be of satisfactory quality or continue to be...
- xpresscf platform: We are developing a pipeline of vaccine candidates utilizing our cell-free protein synthesis platform, which is comprised of the XpressCF® platform exclusively licensed from Sutro Biopharma, Inc. (“Sutro Biopharma”) and our proprietary know-how for vaccine applications against infectious disease. Our future success...
- acip comparable: •obtaining and maintaining Advisory Committee on Immunization Practices (“ACIP”), comparable foreign regulatory authority, professional society, or other clinical recommendation of our vaccine candidates and the willingness of physicians, operators of clinics, and patients to utilize or adopt any of our future...
- authority professional: •obtaining and maintaining Advisory Committee on Immunization Practices (“ACIP”), comparable foreign regulatory authority, professional society, or other clinical recommendation of our vaccine candidates and the willingness of physicians, operators of clinics, and patients to utilize or adopt any of our future...
- professional society: •obtaining and maintaining Advisory Committee on Immunization Practices (“ACIP”), comparable foreign regulatory authority, professional society, or other clinical recommendation of our vaccine candidates and the willingness of physicians, operators of clinics, and patients to utilize or adopt any of our future...
- federal vaccine: New pediatric vaccines that receive an ACIP preferred recommendation are almost universally adopted, and adult vaccines that receive a preferred recommendation are widely adopted. Recent changes to federal vaccine policy have introduced new uncertainties regarding the regulatory, legal, and reimbursement landscape...
- acceptable safety: Due to the significant resources required for the development of our vaccine candidates, we must decide which vaccine candidates to pursue and advance and the amount of resources to allocate to each. Our decisions concerning the allocation of research, development, management and financial resources toward...
Used at least twice, small words left out. Counted, not picked: a phrase can be new because the company renamed something.
What was taken out
17 paragraphs of last year's Risk Factors with nothing like them now. The longest are quoted.
Sources
Item 1A of each 10-K and 10-Q on EDGAR, quoted exactly. Each paragraph links to the filing at sec.gov.
Also
10-K change: what was reworded or cut, section by section.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PCVX/export.csv") into a cell.